Mr. Bogner writes, "While the challenge of treating cardiovascular disease is daunting, I am optimistic about the progress we have made by developing a revolutionary MedTech device that will provide a solution for patients with privilege and without. I am looking forward to the next milestone of our first human use trials in Europe in early 2023." Read more what he has to say.